Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Eyenovia to Participate in Panel Presentation at OSN New York 2018
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
|There are currently no events scheduled.|